Member Info for Marcus134

Well hopefully we get Modi-1 data in RCC within the next couple of months. If results are good maybe the whole platform will be too tempting for Big Pharma to ignore.

Head & neck cancer, Modi-1 ORR of 43% compared to historical ORRs of 19% for Pembrolizumab

Chief Investigator Christian Ottensmeier, Professor of Immuno-Oncology at Head and Neck Institute, University of Liverpool, commented: "This positive preliminary clinical read-out validates the scientific rationale for Moditope® vaccines as a therapy with real potential to improve outcomes achievable with checkpoint inhibitors alone. Given its good safety profile and ease of use, I remain keen to continue using this vaccine as well as explore the application of Modi-1 in the neoadjuvant setting."

Ovarian orr 44%

Dr David Pinato, Principal Investigator at Imperial College, commented:Advanced ovarian cancer is an aggressive cancer which is hard to treat. A disease control rate of 44% with Modi-1 in patients who have exhausted most treatment options is very encouraging

Modi-1 RCC data is due Q3, within 7 weeks.

In case anyone missed this , 21 mins

https://soundcloud.com/citelinesounds/phil-lhuillier-scancell-ceo-on-the-latest-developments-in-cancer-vaccines

Glymab Therapeutics

https://www.youtube.com/watch?v=RZ8yA1XJseY&ab_channel=InvestorMeetCompany

Thanks guys. Pity about that nutters ruining ADVFN. Plenty of good people being put off.

I am optimistic about iScib-1 and Modi-1. Genmab hopefully starts SC129 soon. Glymab news at some point.

Avidimab may be giving that improved PFS at 11 months compared with Scib-1

iScib-1 11 months 81% PFS

Scib-1 11/12 months 65% PFS (stayed at 65% 11-22 months without dropping)

Just a reminder of how amazing iScib-1 would be if we can keep that 80% PFS going beyond the 11 months.

Grandfather of 4 Paul Thomas, 63, from New Milton, Hampshire, was first diagnosed with advanced skin cancer in 2017, and the disease kept returning following treatment.

Last year Paul, who owns a window cleaning business, was given the opportunity to be part of the SCOPE skin cancer vaccine trial which is now part of the NHS Cancer Vaccine Launchpad.

He said: “I feel so lucky to be put on the trial. Thankfully I was still quite fit and since I’ve been on it, my tumours have all shrunk. Every time I go for a scan they seem to be shrinking, which is really exciting.

HTTPS://www.england.nhs.uk/2025/04/skin-cancer-patients-fast-tracked-access-revolutionary-nhs-cancer-vaccine-trial/

Advanced melanoma skin cancer means it has spread to another part of the body such as the liver, lungs or bone.

04-Aug-25 10:02:14 10.60 77 Buy* 10.00 11.00 8.16 O

The code "77" in Market Maker (MM) signals refers to a code used by Market Makers to indicate a potential price increase, often in conjunction with other codes like "700". Specifically, "77" signals can be a way for one Market Maker to instruct another to raise stock prices, potentially leading to immediate price fluctuations

Scancell intending to discuss the trial design with FDA this year, ahead of Cohort 4 data. This is to ensure that the trial can start as soon as is practicable. Scancell also intends to discuss the clinical plans with multiple regulators (ie MHRA in UK and EMA in Europe) and will seek to apply for any relevant accelerated pathways that could be applicable, to try and make iSCIB1+ available to patients as swiftly as possible.

Whilst plans in the unresectable metastatic population are advanced, Scancell is at the very preliminary stages of exploring the potential to investigate iSCIB1+ in earlier stage neoadjuvant/adjuvant resectable melanoma. This is based on activity that has been observed in combination with pembrolizumab.

Based on the now clearly defined target patient population in advanced melanoma, management estimates that the addressable market size for iSCIB1+ in this indication is c $3bn. The opportunity is even larger in the earlier-stage neoadjuvant/adjuvant setting at around $6-9bn.

To date, PFS at 22-months in Cohort 1 is 64.6%, whereas in Cohort 3 the PFS is 80.8% at 11-months, with the combined cohorts shown in Exhibit 4 plotted against SoC data for doublet CPIs ipilimumab/nivolumab (from Checkmate-067).

These data appear to suggest that responses achieved are highly durable and that once a patient has a response, this is maintained – longer follow-up data will be important in this regard. This is perhaps due to the CD8+ killer T-cell responses observed in the majority of patients with a clinical response; these T-cells direct tumour cytotoxicity and promote memory T-cell formation, which contribute to a prolonged clinical benefit. If the effects of iSCIB1+ can be maintained (ie are durable) this is a positive outcome for patients as it means they can live for longer without their disease worsening (a perhaps more meaningful real-world patient benefit than tumour shrinkage, ORR). This compelling PFS benefit has accelerated development plans for a potentially pivotal Phase IIb/III trial, with Scancell planning to meet with FDA later this year.

We expect an update on PFS, with longer follow-up, in Q425, as well as potential initial OS data, in addition to early data from Cohort 4 which is examining intradermal administration (PharmaJet’s Tropis) and an accelerated dosing regimen.

Yes we can`t stay at 10p surely?

Scib-1 dropped to 64.6% at month 11/12 but remained there until month 22.

If iScib-1 stays at 80% from month 4 to 22 months I honestly think it is much more significant than a high ORR that drops off.

I think the market is missing that atm but hopefully Big Pharma likes it.

We will know better when Cohort 4 reports or maybe an update sooner.

It gets EVEN BETTER if we look at the DCR rate of DCR: 25/29 – 86.2%

ORR measures the proportion of patients experiencing a complete response (CR) or partial response (PR). DCR, on the other hand, includes stable disease (SD) in addition to CR and PR, indicating the percentage of patients whose disease is either responding or stable

Hi Chester,

enjoy your posts btw.

The FDA will approve mainly on PFS and not ORR.

The big and important stat is for progression free survival.

PFS 81% at 11m

Now that has stayed constant at 81% from approx month 4 to month 11, amazing!

In contrast Standard of Care Ipi/Nivo(Checkmate-067): PFS

Went from 70% approx at month 4, down to 50% at month 11.

At 22 months it fell to 42%.

HTTPS://scancell.co.uk/wp-content/uploads/2025/07/Scancell-iSCIB1-strongly-improved-outcomes-in-Late-Stage-Melanoma-SCOPE-study-results.pdf